ArticleFrontiers in oncology2025
Response and prognosis to neoadjuvant chemotherapy in women early breast cancer of HER2-low status.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Investigation of the prevalence of HER2-ultralow and the effects of HER2 status (HER2-null vs. HER2-ultralow) on survival in HER2-negative early-stage breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- The Prognostic Impact of HER2 Status and Survival Outcomes in Metastatic Triple Negative Breast Cancer.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: With the significant clinical benefits of antibody-coupled drugs (ADCs) against HER2, the HER2-low-expressing population has come into focus. HER2-low-expressing patients express this membrane protein despite the absence of HER-2 amplification. Whether there is a difference in outcome and prognosis between patients with HER2-low expression and those with HER2-0 expression has not yet been clarified, and more clinical data are needed to characterize them. Methods: Clinical and pathological data of HER2-low versus HER2-0-expressing breast cancer patients treated with neoadjuvant chemotherapy (NACT) and operated at Xinjiang Uygur Autonomous Region Cancer Center from 2015 to 2018 were reviewed, and the patients were analyzed and studied in terms of pathologic complete response (PCR), overall survival (OS) and disease-free survival (DFS). Results: A total of 283 breast cancer patients were included, 102 (36.04%) with HER2-0 expression and 181 (63.96%) with HER2-low expression, with clinical stage II-III. After the study, the pCR rates of HER2-0 and HER2-low tumors were found to be 19.61% and 11.05%, respectively, which were not statistically different ( Conclusion: In breast cancer patients receiving neoadjuvant chemotherapy, no significant differences in chemosensitivity or prognostic outcomes were observed between HER2-low and HER2-0 tumors, considering HR expression subtypes and other current clinicopathological features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.